MedPath

A Blood Based Diagnostic Test for Coeliac Disease

Conditions
Non Coeliac Gluten Sensitivity
Coeliac Disease
Registration Number
NCT02442219
Lead Sponsor
Oslo University Hospital
Brief Summary

Persons with coeliac disease treated with a gluten free diet will be asked to give blood for a new diagnostic blood test. In this test investigators will use multimerized HLA bound to different gliadin-peptides (tetramer) and with the help of a flow-cytometer identify (along with other relevant T-cell-markers) gluten specific T-cells. Investigators believe that these cells will be present in persons with coeliac disease regardless of gluten-intake. Investigators will compare their findings with two control groups; Persons on a gluten free diet where celiac disease is excluded (gluten sensitive group) and persons on a gluten containing diet (healthy control group). In the initial and main study investigators will look at HLA DQ2.5 individuals, which comprise \>90% of all persons with coeliac disease.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
144
Inclusion Criteria
  • HLA DQ2.5 positives in primary blinded study (other HLA-types ie DQ8 and DQ2.2 in later unblinded study)
  • In gluten free group: Diagnosis must be confirmed by duodenal biopsy done after sufficient time on gluten containing diet and participant must have followed a glutenfree diet since.
Exclusion Criteria
  • Drugs that influence the immune system used last three months
  • Infected with Hepatitis B, C or HIV
  • Pregnant

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Ability of the tetramer test in differentiating persons with coeliac disease from controls by the use of tetramer staining for gluten specific T-cells and flowcytometryUpto 20 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Oslo University hospital

🇳🇴

Oslo, Norway

© Copyright 2025. All Rights Reserved by MedPath